,16 As such, stage II endometrial cancer has been broadened by the 2023 FIGO staging system to include nonaggressive histologies with substantial LVSI (stage IIB), aggressive histologies with myometrial invasion (stage IIC), and p53 abnormal cancers of any histology confined to the uterus with any myometrial invasion (stage IICmp53abn).3 The gene discussed is TP53; the disease is endometrial cancer.